Earnings Releases·Nov 12, 2026, 4:12 PM ET

Sensus Healthcare — Third Quarter 2026 Earnings Summary

Revenue declined 13.0% year-over-year to $6.0 million due to the absence of sales to a historically large customer and a product mix shift toward lower-priced SRT-100 systems, though gross margin improved significantly to 55% from 39.1% as cost of sales fell 35.7%.
Net loss widened to $1.5 million ($0.09 per share) from $0.9 million in the prior-year period, while Adjusted EBITDA improved to negative $1.5 million from negative $2.4 million, driven by a 38.9% reduction in R&D expenses.
Unit shipments reached 26 systems (18 new), including two large private equity-backed dermatology groups, with management noting the placement of the 1,000th SRT system subsequent to the quarter end.
The company reported $12.9 million in cash and cash equivalents as of September 30, 2026, and highlighted the implementation of dedicated reimbursement codes to drive broader market adoption.
No changes to future guidance, major strategic M&A activity, or capital return programs were disclosed in the summary.